| Jul 29 |
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
| Jul 29 |
Ventyx Biosciences falls after trial for Crohn’s disease treatment did not meet main goal
|
| Jul 29 |
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
|
| Jul 29 |
Ventyx’s TYK2 drug suffers second setback
|
| Jul 6 |
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
|
| Jul 1 |
Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)
|
| Jun 5 |
Ventyx reports preclinical results for anti-obesity drug VTX3232
|
| Jun 5 |
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
|
